% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{deRojas:144697,
author = {T. de Rojas and B. Kasper and W. Van der Graaf and S. M.
Pfister$^*$ and F. Bielle and T. Ribalta and P. Shenjere and
M. Preusser and S. Fröhling$^*$ and V. Golfinopoulos and M.
Morfouace and M. G. McCabe},
title = {{EORTC} {SPECTA}-{AYA}: {A} unique molecular profiling
platform for adolescents and young adults with cancer in
{E}urope.},
journal = {International journal of cancer},
volume = {147},
number = {4},
issn = {1097-0215},
address = {Bognor Regis},
publisher = {Wiley-Liss},
reportid = {DKFZ-2019-02139},
pages = {1180-1184},
year = {2020},
note = {2020 Aug 15;147(4):1180-1184},
abstract = {For most adolescent and young adult (AYA) cancers,
age-specific molecular features are poorly understood.
SPECTA, an academic translational research infrastructure
for biomaterial collection, will explicitly recruit AYA
patients and will therefore collect empirical data to bridge
the molecular gap between pediatric and adult oncology. The
initial pilot study, activated in Feb-2019 across Europe,
will recruit 100 AYA patients (aged 12-29 years) with
newly diagnosed or relapsed high-grade gliomas and
high-grade bone and soft tissue sarcomas. The primary
objective of the pilot is to determine feasibility and
recruitment rates. Formalin-fixed tumor tissue and whole
blood from study participants will be prospectively
collected with clinical data and stored centrally at the
Integrated BioBank of Luxembourg (IBBL). Whole exome
sequencing (WES) of matched tumor and blood, and tumor RNA
sequencing and DNA methylation profiling will be performed
at the German Cancer Research Center (DKFZ), Heidelberg.
Virtual central pathology review of scanned diagnostic
slides will be undertaken by an international expert panel,
and diagnostic material returned to the participating
centers. A multidisciplinary molecular tumor board will
release a clinically validated report to referring
clinicians within 4-6 weeks after biopsy. SPECTA-AYA
constitutes a major opportunity to gain knowledge about the
tumor biology of this unique age group. It incorporates
notable innovative aspects: AYA specificity, pan-European
academic collaboration, centralized biobanking,
comprehensive molecular profiling, and virtual central
pathology review, among others. SPECTA-AYA will help
untangle the tumor particularities of AYAs with cancer and
aims to improve their access to novel drugs and personalized
medicine. This article is protected by copyright. All rights
reserved.},
cin = {B062 / B340 / HD01},
ddc = {610},
cid = {I:(DE-He78)B062-20160331 / I:(DE-He78)B340-20160331 /
I:(DE-He78)HD01-20160331},
pnm = {312 - Functional and structural genomics (POF3-312)},
pid = {G:(DE-HGF)POF3-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:31465545},
doi = {10.1002/ijc.32651},
url = {https://inrepo02.dkfz.de/record/144697},
}